contact us
An experimental treatment for Duchenne muscular dystrophy has failed a mid-stage study, and Summit Therapeutics said Wednesday it is now stopping work on the drug. Summit shares plunged nearly 80 percent on the news.
Do Not Allow Advertisers to Use My Personal information
